intelligence360
  • SUBSCRIBE
  • About us
  • Video News Daily
  • Contact Us
  • Search Icon

intelligence360

The Intelligent News Source

ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI

ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI

February 1, 2024 Craig Etkin

The funding will support the international expansion and commercial growth of the company and its first-of-its-kind test

February 01, 2024 09:00 AM Eastern Standard Time

SAN FRANCISCO–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today that it has secured an additional $20 million in capital fueled by several prominent large investment funds including Prosperity7 Ventures, Singapore-based global investor EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures, along with investors Navin Chaddha, Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment LLC).

“Investing in ArteraAI wasn’t just a financial decision, but a testament to ArteraAI which is globally revolutionizing patient care”

“The infusion of this additional funding is a crucial catalyst, propelling ArteraAI forward in its mission to personalize cancer therapy through AI-enabled predictive and prognostic tests,” said Andre Esteva, CEO and Co-Founder of ArteraAI. “We are committed to ushering in the era of precision medicine, and stewarding this investment strategically to aid in our international expansion and commercial growth.”

This funding announcement follows closely on the heels of ArteraAI’s recent achievement of the Centers for Medicare and Medicaid Services (CMS) decision on the payment rate for the ArteraAI Prostate Test. The decision helps to ensure broader accessibility to AI-enabled personalized care, benefiting a larger population.

“Investing in ArteraAI wasn’t just a financial decision, but a testament to ArteraAI which is globally revolutionizing patient care,” said Abhishek Shukla at Prosperity7 Ventures. “We are thrilled to be part of the journey as ArteraAI continues its mission to provide patients with access to personalized cancer treatment plans.”

Less than a year ago, ArteraAI emerged from stealth mode with an initial funding of $90M. Since then, the company has made significant strides, obtaining a Medicare payment rate, growing distribution and establishing a solid foundation for international expansion through strategic global partnerships to continue its research.

“ArteraAI’s AI-driven tests represent a transformative approach to designing tailored cancer care regimens. This offers a glimpse into the future where cancer care is truly personalized, aligning with Singapore’s efforts to digitize healthcare and harness AI to enable precision medicine,” said Dr. Jolene Ooi, Senior Principal at EDBI. “We are excited to be part of their growth story and look forward to supporting its foray into Asia.”

To learn more about ArteraAI visit Artera.ai.

About ArteraAI

ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. ArteraAI offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer: ArteraAI Prostate Test.

ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient’s clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis and has been validated using many Phase 3 randomized trials.

ArteraAI Prostate Test is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer. The test is clinically available through our CLIA-certified laboratory in Jacksonville, Florida and can be ordered online at Artera.ai.

About Prosperity7 Ventures

Prosperity7 Ventures is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the world’s leading integrated energy and chemicals company. The fund’s name derives from “Prosperity Well,” the seventh oil well drilled in Saudi Arabia and the first to strike commercial oil, paving the way to prosperity. Bringing forward this pioneering history, Prosperity7 invests globally with a long-term view in breakthrough technologies and transformational business models that bring prosperity and positive impacts on a vast scale. Official website: https://www.prosperity7vc.com/

About EDBI

Investing since 1991, EDBI is a Singapore-based global investor in select high-growth technologies spanning sectors across Information & Communication Technology, Emerging Technology and Healthcare. As a value-creating investor, we support companies aiming to expand in Asia and globally through Singapore with our extensive network, resources and expertise. For more information, visit www.edbi.com

Contacts

Media:
Lesley Swiger
Antenna
lesley.swiger@antennagroup.com
(570) 856-4438

(c)2024 Business Wire, Inc., All rights reserved.


Venture Capital
ArteraAI, Business Wire, California, San Francisco, Venture Capital

Post navigation

NEXT
Willow Innovations has filed a notice of an exempt offering of securities to raise $107,428,861.00 in New Equity Investment.
PREVIOUS
Slumberkins has filed a notice of an exempt offering of securities to raise $3,591,941.00 in New Equity Investment.
Comments are closed.
Subscribe for FREE!

intelligence360

intelligence360
Source: http://go.intelligence360.io/ and https://intelligence360.news/

Infinite Reality, an innovation company powering the next generation of immersive media, AI, and ecommerce, today announced a landmark real estate partnership with renowned real estate investment, development and management firm Sterling Bay to co-develop a 60-acre site in Fort Lauderdale into a next-generation technology and entertainment campus. This ambitious redevelopment—expected to open in 2026—will serve as Infinite Reality’s new global headquarters and is the cornerstone of iR’s long-term real estate strategy, which begins with this flagship project in South Florida. The public-private project marks one of the largest creative economy investments in the area to date, aiming to generate more than 1,000 new jobs with an average salary of six figures and deliver long-term economic growth to the region. Located at 1400 NW 31st Avenue on the site of a remediated former Superfund property, the development features over 100,000 square feet of Class A office space for media, tech, and enterprise clients. Construction is expected to begin in early 2026, pending completion of permitting and design phases.

In a statement John Acunto, co-founder and CEO of Infinite Reality said, “This isn’t just a headquarters—it’s the heart of Infinite Reality’s future. As a proud South Florida resident, this project is deeply personal to me.” “It’s about transforming a community I love into a global hub for immersive technology and creativity. We’re building opportunity, fueling innovation, and laying the foundation for a lasting legacy. Partnering with a world-class development firm like Sterling Bay ensures that this vision is realized at the highest level—and that Fort Lauderdale becomes a defining force in the future of the digital economy.”

In addition to serving as a corporate campus, the site will include flexible spaces for retail, production, digital broadcasting, and entertainment ventures. The development also includes educational initiatives in partnership with local institutions to train and hire future talent in STEM, immersive tech, and creative production. Infinite Reality is an innovation company powering the next generation of digital media and ecommerce through spatial computing, artificial intelligence, and other immersive technologies. Infinite Reality’s suite of cutting-edge software, production, marketing services, and other capabilities empower brands and creators to craft inventive digital experiences that uplevel audience engagement, data ownership, monetization, and brand health metrics.
Source: http://go.intelligence360.io/ and https://intelligence360.news/

Kimberly-Clark Corporation, one of the world's leading manufacturers of personal care and hygiene products, will establish an $800 million advanced manufacturing facility in Trumbull County, bringing an anticipated 491 new high-quality jobs. For Kimberly-Clark, this new facility would be its first in Ohio and represents not just a strategic expansion, but a decisive step in doubling down on growth in the American market. Spread across more than one million square feet, the Warren facility will provide the manufacturing capacity needed to unleash future growth for Kimberly-Clark’s fastest-growing personal care categories that include Baby & Child Care and Adult & Feminine Care. Warren is in geographic proximity to roughly 117 million consumers and will serve as a strategic hub for the Northeast and Midwest regions. Construction is expected to begin this month and will take up to two years.

In a statement Tamera Fenske, chief supply chain officer at Kimberly-Clark said, “Our investment in Warren is a pivotal step forward in our North America business and strategy.” “By establishing a new, state-of-the-art manufacturing facility in Ohio, we’re enhancing our ability to serve millions of consumers across the Midwest and Northeast with greater speed, agility, and resilience. It’s a once-in-a-career opportunity to build a facility from the ground up that reflects the future of manufacturing, and with the support of local partners like JobsOhio, the Department of Development, Lake to River, Western Reserve Port Authority, and local governments, we have the unique opportunity to create high-quality jobs and long-term economic impact in the region.”

Based in Dallas and employing 46,000 people in 34 countries, the company’s portfolio of brands also includes Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus, Plenitud, Sweety, Softex, Viva and WypAll. Its products are sold in more than 175 countries and territories.
Source: http://go.intelligence360.io/ and https://intelligence360.news/

Snorkel AI announced general availability of two new product offerings on the Snorkel AI Data Development Platform: Snorkel Evaluate and Snorkel Expert Data-as-a-Service. These launches advance its mission to turn knowledge into specialized AI—helping teams move from prototype to production at scale by leveraging Snorkel AI’s programmatic data development technology. In addition, Snorkel AI announced it has raised $100 million in Series D funding at a $1.3 billion valuation, led by Addition. This new funding will fuel continued research and innovation in evaluating and tuning specialized AI systems with expert data.


In a statement Alex Ratner, Co-founder and CEO of Snorkel AI said, “We are seeing a surge of momentum around agentic AI, but specialized enterprise agents aren’t ready for production in most settings.” “Enterprises need domain-specific data and expertise to make this a reality. We’re excited to deliver on this need and help AI innovators develop expert data to bring their LLM and agentic systems into production with our new offerings, which round out Snorkel’s unified AI data development stack.”

Snorkel AI is building the Snorkel AI Data Development Platform for evaluating and tuning specialized AI at scale. Snorkel AI’s offerings, including Snorkel Evaluate and Snorkel Expert Data-as-a-Service, accelerate evaluation and tuning of specialized AI systems with expert data—helping teams move from prototype to production at scale by leveraging Snorkel AI’s programmatic data development technology. Launched out of the Stanford AI Lab, Snorkel AI’s platform is used in production by Fortune 500 companies, including BNY, Wayfair, and Chubb, as well as across the U.S. federal government, including the U.S. Air Force.
Load More... Subscribe

Categories

Recent Posts

  • Portal Access, Inc. Announces the closing of $7 Million Series A Financing Round to Support FDA Approval and Limited Market Launch of Next-Generation Chemotherapy Port June 10, 2025
  • CyrusOne to spend $400 Million to occupy 88,874 square feet of space in Whitney Texas. June 10, 2025
  • South Texas Health System to spend $1,936,193.00 to occupy 6,400 square feet of space in Mcallen Texas. June 10, 2025
  • Obvio Raises $22 Million to Deliver AI-Powered Traffic Safety and Prevent Traffic Deaths June 10, 2025

Archives

© 2025   Copyright SI360 Inc. All Rights Reserved.